Compugen Ltd. to Review Fourth Quarter and Year-End 2010 Financial Results on Tuesday, February 15, 2011
08 February 2011 - 11:00PM
Business Wire
Compugen Ltd. (NASDAQ: CGEN) today announced that the Company
plans to host a live conference call and webcast at 10:00 AM EST on
Tuesday, February 15, 2011 to review fourth quarter and year-end
2010 results. The quarterly and year-end results will be released
prior to the conference call.
To access the conference call, please dial 1-888-407-2553 from
the US or 972-3-918-0610 internationally. The call will also be
available via live webcast through Compugen’s website, located at
the following link.
A replay of the conference call will be available approximately
two hours after the completion of the live conference call. To
access the replay, please dial 1-888-295-2634 from the US or
972-3-925-5921 internationally. The replay will be available until
12 noon EST on February 18, 2011.
About Compugen
Compugen is a leading drug and diagnostic product candidate
discovery company. Unlike traditional high throughput trial and
error experimental based discovery, Compugen’s discovery efforts
are based on in silico (by computer) prediction and selection
utilizing a growing number of field focused proprietary discovery
platforms accurately modeling biological processes at the molecular
level. Compugen’s growing number of collaborations with major
pharmaceutical and diagnostic companies cover both (i) the
licensing of product candidates discovered by Compugen during the
validation of its discovery platforms and in its internal research,
and (ii) “discovery on demand” agreements where existing or new
Compugen discovery platforms are utilized to predict and select
product candidates as required by a partner. In 2002, Compugen
established an affiliate, Evogene
Ltd. (www.evogene.com) (TASE: EVGN), to utilize certain
of the Company’s in silico predictive discovery
capabilities in agricultural biotechnology. For additional
information, please visit Compugen's corporate website
at www.cgen.com.
This press release may contain "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements include words such as “may,” “expects,”
“anticipates,” “believes,” and “intends,” and describe opinions
about future events. These forward-looking statements involve known
and unknown risks and uncertainties that may cause the actual
results, performance or achievements of Compugen to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Some of
these risks are: changes in relationships with collaborators; the
impact of competitive products and technological changes; risks
relating to the development of new products; and the ability to
implement technological improvements. These and other factors are
identified and more fully explained under the heading "Risk
Factors" in Compugen's annual reports filed with the Securities and
Exchange Commission.
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024